Chemotargets, a CataloniaBio & HealthTech member, has signed a strategic agreement with the Hospital del Mar Medical Research Institute (IMIM) for the discovery and development of new oncological therapies.
The IMIM Cancer Research Program develops pioneering research in cancer biology, understanding new mechanisms of tumor progression, evaluating new therapies such as immunotherapy, or detecting markers of response to treatment. This program contributes to the creation of new treatments and strategies that optimize therapies from the beginning, avoiding ineffective treatments with multiple side effects, and progressing to a personalized high-quality medicine.
Thanks to the computational technology that Chemotargets will provide, the process will be easier and faster and drugs that act on targets or mechanisms for which there is currently no effective treatment can be identified.
Photo: Jordi Mestres, founder of Chemotargets, at the Barcelona Science Park - © Chemotargets
You also be interested in:
Comments